Opioid Stewardship

Orthopedic surgery can be performed in hospital outpatient departments (HOPDs) and ambulatory surgical centers (ASCs), as well as in traditional inpatient venues. Patients who undergo orthopedic surgery may be prescribed opioids for the management of postsurgical pain. However, the association between surgery venue, postsurgical opioid use, and health care costs remains unclear.

AMCP supports regulatory and legislative provisions relating to opioid management that ensure appropriate patient access and treatment of uncontrolled pain, while limiting abuse and diversion of opioids and opioid potentiators. .

An analysis published in JMCP found that patients in the North Carolina Medicaid program continued to receive opioids and benzodiazepines concurrently despite known risks. Read the results and recommendations that may benefit this and other Medicaid populations.

A retrospective claims analysis in JMCP found that patients who received an outpatient opioid prescription following surgery had significantly increased health care utilization and costs for the following year.

A retrospective claims analysis in JMCP found that patients who received an outpatient opioid prescription following surgery had significantly increased health care utilization and costs for the following year.

The benefits of extended release opioid agonists and antagonists in the highly personalized space of opioid use disorder treatment are described in this JMCP article by the CMO of Drug & Alcohol Treatment Centers, Pathway Healthcare.

Extended-release opioid agonists and antagonists represent an alternative treatment strategy for opioid use disorder. However their value is low for the money, according to this summary of an ICER analysis published in JMCP.

Extended-release opioid agonists and antagonists represent an alternative treatment strategy for opioid use disorder. However their value is low for the money, according to this summary of an ICER analysis published in JMCP.

The benefits of extended release opioid agonists and antagonists in the highly personalized space of opioid use disorder treatment are described in this JMCP article by the CMO of Drug & Alcohol Treatment Centers, Pathway Healthcare.